Detalhe da pesquisa
1.
Cost-Effectiveness Analysis of Nefecon versus Best Supportive Care for People with Immunoglobulin A Nephropathy (IgAN) in the United States.
Clinicoecon Outcomes Res
; 15: 213-226, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37020570
2.
A Systematic Literature Review of the Epidemiology, Health-Related Quality of Life Impact, and Economic Burden of Immunoglobulin A Nephropathy.
J Health Econ Outcomes Res
; 8(2): 36-45, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-34692885
3.
Cost-Effectiveness Analysis of Regorafenib for Gastrointestinal Stromal Tumour (GIST) in Germany.
Clin Drug Investig
; 37(6): 525-533, 2017 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-28361439
4.
The economic burden of common adverse events associated with metastatic colorectal cancer treatment in the United States.
J Med Econ
; 20(1): 54-62, 2017 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-27603498